Levofloxacin

is prescribed to treat:

• Bacterial pneumonia, sinusitis, and urinary tract infections • Various related conditions in the antibiotics category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Levofloxacin (Levaquin) is a fluoroquinolone antibiotic used for community-acquired pneumonia, complicated urinary tract infection and pyelonephritis, sinusitis in specific circumstances, and skin and intra-abdominal infections. It is the respiratory fluoroquinolone, and like the rest of its class it carries adverse effects serious enough that regulators have restricted its use for common infections.

Mechanism of Action

Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, the enzymes that manage DNA supercoiling during replication. Blocking them causes double-strand breaks and rapid bacterial death, so fluoroquinolones are bactericidal.

What distinguishes levofloxacin from ciprofloxacin is enhanced Gram-positive activity, particularly against Streptococcus pneumoniae — the principal bacterial cause of community-acquired pneumonia. Ciprofloxacin covers pneumococcus poorly, which is why it is not a respiratory agent despite excellent Gram-negative coverage.

Levofloxacin also covers atypical respiratory pathogens — Legionella, Mycoplasma, Chlamydophila — which conventionally require a macrolide. That breadth means a single oral drug can cover both typical and atypical pneumonia, which is precisely why it became so widely used and why it is now so heavily resistant.

Oral bioavailability approaches that of the intravenous form, allowing serious infections to be treated orally that would otherwise need admission.

The Safety Restrictions

The FDA has issued multiple boxed warnings for fluoroquinolones, and they are the central fact about this class rather than a footnote.

Tendinitis and tendon rupture, most often of the Achilles, can occur during treatment or months afterwards, with substantially higher risk over age 60, with concurrent corticosteroids such as prednisone, and in transplant recipients.

Peripheral neuropathy can begin rapidly after starting and may be permanent. Central nervous system effects include confusion, agitation, insomnia, and less commonly hallucinations and seizures — in older patients these are regularly attributed to the infection or to delirium rather than to the antibiotic.

Aortic aneurysm and dissection risk is increased, relevant in patients with existing aneurysm, Marfan syndrome, or significant atherosclerosis. Fluoroquinolones can exacerbate myasthenia gravis.

Because of these, the FDA advises against fluoroquinolones for uncomplicated urinary tract infection, acute sinusitis, and acute bronchitis when other options exist — the risks exceed the benefits for infections that are self-limiting or treatable with safer agents. Acute bronchitis in particular is viral in the great majority of cases and should not be receiving a fluoroquinolone at all. The FDA fluoroquinolone safety communication sets this out.

Clinical Use

Levofloxacin is appropriate for community-acquired pneumonia in patients with comorbidities or recent antibiotic exposure, where a beta-lactam plus macrolide would be the alternative; for complicated urinary infection and pyelonephritis where culture supports it; and for specific indications including some bone, joint, and intra-abdominal infections.

For uncomplicated cystitis it should generally not be used — nitrofurantoin, trimethoprim-sulfamethoxazole, and fosfomycin are effective, safer, and less damaging to the resistance landscape. For uncomplicated sinusitis, amoxicillin or amoxicillin-clavulanate is preferred where treatment is warranted at all.

Absorption is markedly reduced by calcium, magnesium, iron, zinc, and aluminium — dairy, antacids, supplements, and multivitamins must be separated by at least two hours before or after. This is a frequent cause of treatment failure that looks like resistance. Our pulmonary team manages pneumonia that is not responding.

Course lengths have shortened with evidence, and this matters more with fluoroquinolones than with safer classes because adverse effects accrue with exposure.

Monitoring and Follow-Up

Short courses need no routine laboratory monitoring in healthy patients. Culture and sensitivity results should be reviewed and therapy narrowed — levofloxacin is frequently continued empirically when a culture has already shown a safer agent would work, and narrowing partway through a course is legitimate and under-used.

Levofloxacin prolongs the QT interval, and combining it with other QT-prolonging drugs warrants attention to potassium and magnesium. Blood glucose can move in either direction, and severe hypoglycemia has been reported, particularly in older patients taking sulfonylureas such as glipizide.

It interacts with warfarin, raising INR. Unlike ciprofloxacin, levofloxacin does not meaningfully inhibit CYP1A2, so it does not raise theophylline or caffeine levels to the same degree. The MedlinePlus levofloxacin entry covers the interaction profile.

Where a fluoroquinolone genuinely is the right choice, the case is usually about coverage that nothing else provides orally: atypical plus typical respiratory pathogens in one agent, Pseudomonas coverage, or oral therapy for an infection that would otherwise require intravenous access and admission. Those are real advantages and they justify the risks in the right patient.

What does not justify them is convenience. A single once-daily oral drug that covers almost everything is appealing precisely when the diagnosis is uncertain, and that is exactly the situation where a narrower agent or no antibiotic at all is usually correct. The question worth asking before prescribing is not whether levofloxacin will work, but whether something safer would work equally well.

Special Populations

In older adults, tendon rupture, CNS effects, aortic risk, and hypoglycemia are all substantially more likely, and a safer alternative should be sought where possible. Concurrent corticosteroids compound tendon risk considerably.

In pregnancy fluoroquinolones are generally avoided. In children they are reserved for specific situations where no alternative exists, given effects on developing cartilage in animal studies. Kidney impairment requires dose adjustment. Patients with myasthenia gravis, known aortic aneurysm, or prior fluoroquinolone-associated tendon injury should not receive them.

When to Contact Your Doctor

Stop the drug and seek advice for new pain, swelling, or tenderness in a tendon — particularly the back of the ankle — since continuing raises rupture risk. Report new numbness, tingling, burning, or weakness in the hands or feet promptly, as early discontinuation improves the chance of recovery.

Seek urgent care for sudden severe chest, abdominal, or back pain, which can indicate aortic dissection. Report confusion, agitation, hallucinations, severe insomnia, or mood change. Palpitations or fainting warrant evaluation, as does severe or persistent watery diarrhoea. Symptoms of low blood sugar need immediate treatment and review.

Report failure to improve within two to three days of starting treatment for pneumonia.

To discuss whether a fluoroquinolone is the right choice, or review a safer alternative, contact us or schedule a visit.